A major eye care company announced Tuesday its optimistic outlook for the next two years, projecting steady revenue increases driven by new medical device launches and surgical equipment.
Swiss-based Alcon released forecasts showing anticipated sales growth between 5% and 7% through 2026, aligning closely with Wall Street predictions of approximately $11.13 billion in revenue. The company attributes this positive outlook to strong performance from its surgical platforms and contact lens divisions, even while facing headwinds from international trade policies.
Company officials warned that tariff-related expenses could reach between $125 million and $175 million in 2026, even after implementing cost-saving measures.
The firm also noted that expansion in Chinese markets may face challenges due to government procurement policies and broader economic uncertainties in the region.
Alcon’s recent performance has been bolstered by consistent demand for cataract surgery procedures, which medical experts consider essential treatments for aging patient populations rather than elective procedures.
During the final quarter of last year, the company’s surgical division generated $1.55 billion in revenue, marking a 9% increase. Equipment sales surged 21% following the introduction of new products, including the Unity surgical tools platform. Meanwhile, consumable products, which provide ongoing revenue streams, grew by 8%.
However, the company’s operating margin decreased to 11.6% in the fourth quarter, down from 15.9% the previous year. This decline resulted from increased investments in new product development and higher research costs, along with tariff-related expenses.
Market analysts are closely watching whether momentum from products like PanOptix Pro and newer equipment platforms can maintain growth trajectories through 2026, particularly as the company navigates supply chain challenges and pricing pressures.
